[go: up one dir, main page]

IN2012DN03130A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03130A
IN2012DN03130A IN3130DEN2012A IN2012DN03130A IN 2012DN03130 A IN2012DN03130 A IN 2012DN03130A IN 3130DEN2012 A IN3130DEN2012 A IN 3130DEN2012A IN 2012DN03130 A IN2012DN03130 A IN 2012DN03130A
Authority
IN
India
Prior art keywords
propofol
compositions
aerosols
buccal
capsules
Prior art date
Application number
Inventor
Bastian Theisinger
Sonja Theisinger
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Publication of IN2012DN03130A publication Critical patent/IN2012DN03130A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C19/00Acyclic saturated compounds containing halogen atoms
    • C07C19/08Acyclic saturated compounds containing halogen atoms containing fluorine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides novel pharmaceutical compositions comprising the active ingredient propofol. Preferably, propofol is dissolved in at least one semifluorinated alkane. The compositions, which are preferably liquid or gel-like, may optionally comprise further excipients. They may be used as fill material in capsules, as buccal or nasal sprays, or as aerosols for pulmonary administration. They are particularly useful for the transmucosal administration of propofol.
IN3130DEN2012 2009-11-23 2010-11-22 IN2012DN03130A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09014548A EP2332525A1 (en) 2009-11-23 2009-11-23 Pharmaceutical composition comprising propofol
PCT/EP2010/067938 WO2011061332A1 (en) 2009-11-23 2010-11-22 Pharmaceutical composition comprising propofol

Publications (1)

Publication Number Publication Date
IN2012DN03130A true IN2012DN03130A (en) 2015-09-18

Family

ID=41694756

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3130DEN2012 IN2012DN03130A (en) 2009-11-23 2010-11-22

Country Status (12)

Country Link
US (1) US8796340B2 (en)
EP (2) EP2332525A1 (en)
JP (1) JP5707009B2 (en)
KR (1) KR20120104262A (en)
CN (1) CN102753159B (en)
AU (1) AU2010320823B2 (en)
BR (1) BR112012012108A2 (en)
CA (1) CA2776855C (en)
ES (1) ES2450423T3 (en)
IN (1) IN2012DN03130A (en)
MX (1) MX2012005881A (en)
WO (1) WO2011061332A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011113855A2 (en) 2010-03-17 2011-09-22 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
DK2714008T3 (en) 2011-05-25 2017-03-13 Novaliq Gmbh PHARMACEUTICAL COMPOSITION FOR APPLICATION ON NAIL
ES2623233T3 (en) 2011-05-25 2017-07-10 Novaliq Gmbh Topical pharmaceutical composition based on semi-fluorinated alkanes
GB201116271D0 (en) 2011-09-21 2011-11-02 Univ Cardiff Dispersion anaesthetic device
KR101989648B1 (en) 2012-01-23 2019-06-14 노바리크 게엠베하 Stabilised protein compositions based on semifluorinated alkanes
PL3488847T3 (en) 2012-09-12 2024-04-08 Novaliq Gmbh Semifluorinated alkane compositions
PT2708228T (en) * 2012-09-12 2018-10-09 Novaliq Gmbh Eye wash compositions
EP3100722B1 (en) 2012-09-12 2024-03-20 Novaliq GmbH Semifluorinated alkanes for use in solubilizing meibum
US10273298B2 (en) 2013-07-23 2019-04-30 Novaliq Gmbh Stabilized antibody compositions
EP2944324A1 (en) * 2014-05-13 2015-11-18 LTS LOHMANN Therapie-Systeme AG Use of semifluorinated alkanes in transdermal therapeutic systems
WO2016061538A1 (en) 2014-10-16 2016-04-21 The Board Of Trustees Of The Leland Stanford Junior University Novel methods, compounds, and compositions for anesthesia
ES2803248T3 (en) 2015-09-30 2021-01-25 Novaliq Gmbh 2-perfluorohexyl octane for ophthalmic administration
CN120884568A (en) 2015-09-30 2025-11-04 诺瓦利克有限责任公司 semifluorinated compounds and their compositions
KR102257916B1 (en) 2016-06-23 2021-05-28 노바리크 게엠베하 Kit including drop dispenser
JP7012075B2 (en) 2016-09-22 2022-01-27 ノバリック ゲーエムベーハー Pharmaceutical composition for use in the treatment of blepharitis
CN109906085B (en) 2016-09-23 2024-03-08 诺瓦利克有限责任公司 Ophthalmic compositions containing cyclosporine
CN110267645A (en) 2016-12-23 2019-09-20 诺瓦利克有限责任公司 Ophthalmic compositions for the treatment of dry eye
WO2018193093A1 (en) 2017-04-21 2018-10-25 Novaliq Gmbh Iodine compositions
EP3621601A1 (en) 2017-05-12 2020-03-18 Novaliq GmbH Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
WO2019063551A1 (en) 2017-09-27 2019-04-04 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
WO2019068763A1 (en) 2017-10-04 2019-04-11 Novaliq Gmbh Ophthalmic compositions comprising f6h8
KR20200128407A (en) 2018-03-02 2020-11-12 노바리크 게엠베하 Pharmaceutical composition containing nebivolol
JP2021522219A (en) 2018-04-27 2021-08-30 ノバリック ゲーエムベーハー Ophthalmic composition containing tafluprost for the treatment of glaucoma
EP3856124A1 (en) 2018-09-27 2021-08-04 Novaliq GmbH Lipid barrier repair
AU2019358249B2 (en) 2018-10-12 2024-02-22 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
US12397039B2 (en) 2019-02-13 2025-08-26 Novaliq Gmbh Compositions and methods for the treatment of ocular neovascularization
CA3149046A1 (en) 2019-09-06 2021-03-11 Jorg Haisser Ophthalmic composition for the treatment of uveitis
EP3912622A1 (en) 2020-05-19 2021-11-24 tesa Labtec GmbH Oral film for safe administration of api

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496537A (en) * 1995-03-23 1996-03-05 Henry; Richard A. Propofol hydrofluorocarbon propellant formulations
DE19536504C2 (en) * 1995-09-29 1999-09-23 H Meinert Use of fluorinated alkanes
EP1124416A1 (en) * 1999-03-15 2001-08-22 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
GB0124071D0 (en) * 2001-10-08 2001-11-28 Kbig Ltd Improvement in the administration of high boiling point aneasthetics
CA2549524A1 (en) * 2004-01-02 2005-07-28 Wisconsin Alumni Research Foundation Encapsulation of chemical compounds in fluorous-core and fluorous-inner-shell micelles formed from semifluorinated-block or fluorinated-block copolymers
DE102004030044A1 (en) 2004-06-22 2006-01-12 Birken Gmbh Triterpene-containing oleogel, triterpene-containing oleogel and process for the preparation of a triterpenhaltigen oleogel
EP2099408B1 (en) * 2006-11-28 2016-10-05 Wisconsin Alumni Research Foundation Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics
EP2110126B9 (en) * 2008-04-18 2012-09-19 Novaliq GmbH Inhalative and instillative use of semi-fluorised alkanes as active ingredient carriers in the intrapulmonary area

Also Published As

Publication number Publication date
ES2450423T3 (en) 2014-03-24
CA2776855C (en) 2017-10-24
AU2010320823B2 (en) 2014-06-26
EP2503999B1 (en) 2013-12-25
BR112012012108A2 (en) 2016-04-05
EP2503999A1 (en) 2012-10-03
CN102753159A (en) 2012-10-24
US8796340B2 (en) 2014-08-05
CA2776855A1 (en) 2011-05-26
WO2011061332A1 (en) 2011-05-26
KR20120104262A (en) 2012-09-20
JP5707009B2 (en) 2015-04-22
JP2013511496A (en) 2013-04-04
US20120238639A1 (en) 2012-09-20
EP2332525A1 (en) 2011-06-15
AU2010320823A1 (en) 2012-07-12
MX2012005881A (en) 2012-06-19
CN102753159B (en) 2014-03-12

Similar Documents

Publication Publication Date Title
IN2012DN03130A (en)
MX2013001677A (en) Stable formulations of linaclotide.
BR112014009087A2 (en) xylitol stabilized etanercept formulations
WO2011041729A3 (en) Compounds as lysophosphatidic acid receptor antagonists
WO2011017350A3 (en) Compounds as lysophosphatidic acid receptor antagonists
WO2011041461A3 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
EA201290982A1 (en) PHARMACEUTICAL COMPOSITIONS, PREVENTING ABUSE
BR112012012081A2 (en) method for processing a kobit medical image file in a protocol-guided imaging procedure, equipment for processing a medical image file obtained by a protocol-guided imaging procedure and computer program design containing instruction sets
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
MX2011011428A (en) Sulfamoyl benzoic acid derivatives as trpm8 antagonists.
MX2012001660A (en) Linaclotide-containing formulations for oral administration.
PH12012500754A1 (en) Pharmaceutical composition comprising oligopeptides
EA201590805A1 (en) COMPOSITION WITH IMMEDIATE AND PROLONGED DELIVERY
WO2010021607A3 (en) Pharmaceutical formulation
WO2011157722A3 (en) Solid ivabradine-containing composition
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
EP3228311A3 (en) Pharmaceutical and nutraceutical compositions of abscisic acid
WO2013134534A3 (en) Solid state forms of cabazitaxel and processes for preparation thereof
WO2011069037A3 (en) Stabilization and storage of biological pharmaceutical compositions
WO2010049449A3 (en) Novel salts of sunitinib
UA110979C2 (en) Liquid pharmaceutical formulation comprising nitisinone
MX2010004899A (en) Novel neurturin conjugates for pharmaceutical use.
EA201200485A1 (en) ORAL FALLING PHARMACEUTICAL DRUG FORM CONTAINING AIPIPRAZOL
WO2013114400A3 (en) Compressed pharmaceutical compositions of atypical antipsychotics